Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
307.05(c) 299.15(c) 297.25(c) 297.4(c) 298.35 Last
1 697 398 2 767 307 2 450 057 2 046 400 452 295 Volume
-1.41% -2.57% -0.64% +0.05% +0.32% Change
More quotes
Financials
Sales 2020 60 385 M 66 677 M 66 677 M
Net income 2020 14 670 M 16 199 M 16 199 M
Net cash position 2020 3 206 M 3 540 M 3 540 M
P/E ratio 2020 17,7x
Yield 2020 3,13%
Sales 2021 63 259 M 69 850 M 69 850 M
Net income 2021 16 031 M 17 701 M 17 701 M
Net cash position 2021 12 035 M 13 289 M 13 289 M
P/E ratio 2021 15,9x
Yield 2021 3,24%
Capitalization 254 B 281 B 281 B
EV / Sales 2020 4,16x
EV / Sales 2021 3,83x
Nbr of Employees 97 735
Free-Float 83,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
11/09Presentation
More about the company
Notations Surperformance© of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
All news about ROCHE HOLDING AG
10/23CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results
AQ
10/22ROCHE HOLDINGS AG : Goldman Sachs maintains a Buy rating
MD
10/22PTC THERAPEUTICS : Evrysdi Continues to Make Global Progress for the Treatment o..
AQ
10/22ROCHE : Atea team up on potential COVID-19 pill
RE
10/22ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..
PU
10/22ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..
PU
10/22ROCHE : announces collaboration with Atea Pharmaceuticals to develop a potential..
AQ
10/22ROCHE : Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Dev..
AQ
10/22Roche announces collaboration with Atea Pharmaceuticals to develop a potentia..
GL
10/21ROCHE : COVID SCIENCE-COVID-19 complication rates far higher than for flu; open ..
RE
10/21PROTHENA : Shares Rise 7% on Prasinezumab Study With Roche
DJ
10/21PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
10/21ROCHE : and Prothena will Advance Prasinezumab into Late-Stage Clinical Developm..
AQ
10/20ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
More news
News in other languages on ROCHE HOLDING AG
10/23Roche compte continuer à se développer sur le continent africain
10/23AVIS D'ANALYSTES DU JOUR : Air France-KLM, BioMérieux, Logitech, Michelin, Nestl..
10/22ROCHE HOLDINGS AG : Goldman Sachs toujours positif
10/22Goldman senkt Ziel für Roche - 'Conviction Buy List'
10/22ROCHE : nouveau partenariat dans la lutte contre le Covid-19
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 08/19
Close to an important medium term support level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 379,06 CHF
Last Close Price 297,40 CHF
Spread / Highest target 46,6%
Spread / Average Target 27,5%
Spread / Lowest Target -4,17%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-5.29%280 884
JOHNSON & JOHNSON-0.43%382 350
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999
NOVO NORDISK A/S15.16%164 690